NOT-HL-21-031: Notice of NHLBI Participation in PAR-21-154, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)"

Notice of NHLBI Participation in PAR-21-154, "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)"

Notice Number:

NOT-HL-21-031

Key Dates

Release Date:

September 10, 2021

Related Announcements

PAR-21-154 - Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

This Notice announces that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in Funding Opportunity Announcement (FOA) PAR-21-154 "Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)".

The following modifications have been added to PAR-21-154, reflecting NHLBI's participation in this FOA:

Currently Reads:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)
National Eye Institute (NEI)
National Human Genome Research Institute (NHGRI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Nursing Research (NINR)
National Cancer Institute (NCI)

Assistance Listing Number(s)

93.279, 93.867, 93.172, 93.866, 93.273, 93.395, 93.399, 93.393, 93.394, 93.396, 93.853, 93.865, 93.173, 93.242, 93.361

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Components of Participating Organizations

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.279, 93.867, 93.172, 93.866, 93.273, 93.395, 93.399, 93.393, 93.394, 93.396, 93.853, 93.865, 93.173, 93.242, 93.361, 93.837, 93.838, 93.839, 93.840, 93.233

Additionally, the following section was modified to add:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

The NHLBI supports basic and clinical research pertaining to the structure, function, and diseases of the cardiovascular system, lungs, blood and blood vessels, and sleep disorders. The NHLBI also supports research in stem cell biology and transplantation, transfusion medicine, and blood resources. The NHLBI carries out its mission through a number of research programs that provide support for projects ranging from studies at the molecular level to whole body studies in man and animals. Examples of research areas supported by the NHLBI include atherosclerosis, hypertension, cerebrovascular disease (directed at the dependent variable of blood, heart, or blood vessel), coronary heart disease, peripheral vascular diseases, arrhythmias, heart failure, and shock, congenital and rheumatic heart diseases, cardiomyopathies and infections of the heart, circulatory assistance, lung cell and molecular biology, chronic obstructive lung diseases, pediatric pulmonary diseases, cystic fibrosis, sleep-disordered breathing, asthma, fibrotic and immunologic lung diseases, acute respiratory failure, pulmonary vascular diseases, HIV-associated lung disorders and bone marrow suppression, bleeding and clotting disorders, disorders of the red blood cell such as sickle cell disease and Cooley's anemia, bone marrow failure syndromes, and blood resources.

All remaining aspects of the FOA PAR-21-154 remain the same.

Inquiries

Please direct all inquiries to:

Aaron D. Laposky, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-7837
Email: [email protected]